Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Antigen specificity of clonally enriched CD8<sup>+</sup> T cells in multiple sclerosis.

Nature immunology·2026
Same author

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis.

Nature medicine·2025
Same author

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.

Annals of neurology·2025
Same journal

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

The New England journal of medicine·2026
Same journal

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026
Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Advances in Multiple Sclerosis.

Stephen L Hauser1

  • 1UCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco, San Francisco.

The New England Journal of Medicine
|July 1, 2026
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is an autoimmune disease damaging the central nervous system. While treatments help relapsing MS, progressive forms need therapies to prevent worsening and repair myelin.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: Jul 3, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

  • Neuroimmunology
  • Neurology
  • Autoimmune Disorders

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system's myelin.
  • Immune-mediated myelin damage causes inflammation, neurodegeneration, and progressive disability.
  • Common symptoms include visual disturbances, sensory issues, weakness, and balance problems.

Purpose of the Study:

  • To review current understanding of multiple sclerosis pathophysiology and treatment.
  • To highlight advances in managing relapsing forms of MS.
  • To identify unmet needs in treating progressive MS and promoting myelin repair.

Main Methods:

  • Literature review of multiple sclerosis research.
  • Analysis of therapeutic strategies for relapsing and progressive MS.
  • Evaluation of symptom management and lifestyle support in MS care.

Main Results:

  • Significant treatment advances, including CD20-targeting monoclonal antibodies, benefit relapsing MS.
  • Limited therapeutic options exist for progressive forms of MS.
  • Symptom management and lifestyle support are crucial for MS patients.

Conclusions:

  • While relapsing MS outcomes have improved, progressive MS requires novel therapies.
  • Developing treatments to halt progression and promote myelin repair is a critical need.
  • Integrated care including symptom management and lifestyle support enhances quality of life for individuals with MS.